ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2024
Complete response (CR) observed in 85% (17/20) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) — ImPact … Continued
ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin n VTP in Low Grade UTUC at EMUC 2024
Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) — ImPact … Continued
ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024
TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporn vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporn VTP treatment of patients with low-grade upper … Continued
ImPact Biotech to Present at Oppenheimer Private Life Sciences Company Showcase
TEL AVIV, Israel, Sept. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that management will present a corporate overview at the Oppenheimer Private Life Sciences Company Showcase on October 1 st, 2024 in New … Continued
ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program
TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padelipor n vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced investment commitment of €13.5M from the European Innovation Council’s (EIC) Accelerator program, including a grant of €2.5M and a conditional equity investment … Continued